Qiagen (NYSE:QGEN) Hits New 1-Year Low – Here’s What Happened

Qiagen N.V. (NYSE:QGEN) hit a new 52-week low during trading on Friday . The stock traded as low as $38.89 and last traded at $38.9710, with a volume of 195374 shares traded. The stock had previously closed at $39.71.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Jefferies Financial Group restated a “buy” rating and issued a $59.00 price objective on shares of Qiagen in a research note on Thursday, February 5th. Weiss Ratings restated a “hold (c)” rating on shares of Qiagen in a research report on Monday, December 29th. Barclays set a $58.00 price objective on shares of Qiagen and gave the company an “overweight” rating in a research report on Friday, February 6th. UBS Group set a $52.00 target price on Qiagen in a research report on Monday, February 9th. Finally, Zacks Research cut Qiagen from a “hold” rating to a “strong sell” rating in a report on Monday, March 9th. Five investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $55.20.

Qiagen Stock Performance

The firm has a market capitalization of $8.05 billion, a price-to-earnings ratio of 19.37, a price-to-earnings-growth ratio of 1.91 and a beta of 0.70. The firm’s 50-day moving average price is $47.70 and its two-hundred day moving average price is $48.20. The company has a debt-to-equity ratio of 0.44, a quick ratio of 3.31 and a current ratio of 3.90.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, February 4th. The company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.01. Qiagen had a return on equity of 14.56% and a net margin of 20.33%.The company had revenue of $540.42 million for the quarter, compared to the consensus estimate of $528.53 million. During the same period in the previous year, the business earned $0.61 earnings per share. The company’s quarterly revenue was up 3.6% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. Sell-side analysts predict that Qiagen N.V. will post 2.26 earnings per share for the current year.

Institutional Investors Weigh In On Qiagen

Several institutional investors and hedge funds have recently made changes to their positions in the company. Danske Bank A S bought a new position in Qiagen during the 3rd quarter valued at about $36,000. Smartleaf Asset Management LLC increased its holdings in shares of Qiagen by 1,383.3% during the third quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock worth $39,000 after buying an additional 830 shares in the last quarter. Manchester Capital Management LLC bought a new position in shares of Qiagen in the fourth quarter valued at approximately $42,000. MAI Capital Management raised its stake in shares of Qiagen by 998.9% in the second quarter. MAI Capital Management now owns 978 shares of the company’s stock valued at $47,000 after acquiring an additional 889 shares during the last quarter. Finally, Global Retirement Partners LLC boosted its holdings in shares of Qiagen by 279.9% in the 4th quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock worth $52,000 after acquiring an additional 851 shares in the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.